The Hepatoclastoma Research Foundation (HRF) is proud to announce a research study which will (. . . )reveal how cannabis (the main psychoactive component in cannabis) helps to normalize the fate of damaged AAV (aviruses) in the body.

Four clinical trial participants enrolled in the study are enrolled at two large North American biomedical research institutes: The University of Eastern Finland in Aarhus Denmark in St Petersburg and University of Royal London in the UK. They are Anneke Maarihi a Ph. D. student Oyo Peky Ph. D. a research post-doctoral fellow and Vassy Sergeev Ph. D. a local pharmacist and consultant respectively at clinics in each city. As part of the study the AAV rhodopsin transporter and its receptor (in this case cAd64-7p) were induced into a culture dish with standard cannabis high enough levels to activate the cell. The cells express three types of receptors. Some accept cannabinoid particles. The rest bind to the virus protein for degradation or neutralization. AE antibodies are a type of natural antibodies which react with their metabolites to some degree said Professor Justine Daigle a Shintomi University researcher at the University of Eastern Finland.

Everything is being done at the SciLifeLab in Dugovka. The study is made possible thanks to the collaboration among Opamore Medical Laboratories Ltd. Stepland and specialists at SickKids Hospital in Glasgow. Specialriers will form a commission committee in December which will allocate two seats to HRF with respect for a push for joint research and technological advancement.

Haematologists and cancer researchers are involved in this new phase study. The investigational clinical purpose could be explored in the form of a small-molecule drug mediated by Cannabis.

We are planning to test the safety and efficacy of different doses of tetrahydrocannabinol (THC) in animal models of chronic lymphocytic leukemia (CLL) in which THC is being used as a treatment. THC is the main psychoactive constituent of cannabis with THC doses ranging from 50mg to 210mg in experimental models said AProf Daigle.

The study has been facilitated by Opamore Medical Laboratories Ltd. Stepland completed the opening of a separate research center in Dunuesdal. This facility is funded by the SEK Foundation and Drug Testings World Anti-Drug Research Foundation (DDRF) a Global and US initiative.